Malaria Clinical Trial
— TETRDC2016Official title:
Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial
Verified date | November 2017 |
Source | Ministry of Public Health, Democratic Republic of the Congo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Democratic Republic of the Congo (DRC) is among the countries most affected by malaria in
Sub-Saharan Africa. Condidering its size and the geographic position, the DRC is meant to
play a major role in the malaria control in the region. The National Malaria Control program
recommends artemisinin-based combination treatments (ACTs), in particular
artesunate-amodiaquine or artemether-lumefrantrine for the treatment of uncomplicated
malaria. Previous studies indicated that ACTs are still effective, with efficacy above the
required threshold of 90%. It is required to assess regularly the efficacy of antimalarial
drugs, in order to ascertain the relevance of treatment guidelines such that, in case of
increasing failure rates, alternative options can be decided ontime.
The purpose of this trial is to assess efficacy and safety of artesunate-amodiaquine (ASAQ
Winthrop®), artemether-lumefantrine (Coartem Dispersible®) and
dihydro-artemisinin-piperaquine (Eurartesim®) at day 42 in the treatment of uncomplicated
Plasmodium falciparum malaria in six surveillance sites around DRC.
Status | Completed |
Enrollment | 1615 |
Est. completion date | January 2, 2018 |
Est. primary completion date | January 2, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 59 Months |
Eligibility |
Inclusion Criteria: - children aged 6 to 59 months - axillary temperature = 37.5 °C or history of fever during the 24 h before recruitment - monoinfection with Plasmodium falciparum with asexual parasite count of 2,000 to 200,000/µL - ability to swallow oral medication - ability and willingness to comply with the protocol for the duration of the study and to comply with the study visit schedule - informed consent from a parent/guardian - absence of general danger signs or signs of severe falciparum malaria according to the definitions of WHO (2000) - absence of severe malnutrition according to WHO child growth standards - absence of febrile condition due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal or hepatic diseases, HIV/AIDS) - absence of regular medication, which might interfere with antimalarial pharmacokinetics - absence of history of hypersensitivity reactions or contraindication to any medicine being tested or used as alternative treatment Exclusion Criteria: - presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO - body weight < 5kg - hemoglobin level < 5g/ dL - mixed or monoinfection with another Plasmodium species detected by microscopy - presence of severe malnutrition - presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS) - regular medication, which may interfere with antimalarial pharmacokinetics; - history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s) |
Country | Name | City | State |
---|---|---|---|
Congo, The Democratic Republic of the | Centre de santé Bolenge | Bolenge | Equateur |
Congo, The Democratic Republic of the | Centre de Santé Foyer Social | Kabondo | Tshopo |
Congo, The Democratic Republic of the | Centre de Santé Lupidi 1 | Kapolowe | Haut-Katanga |
Congo, The Democratic Republic of the | Centre de Santé de Référence Mikalayi | Kazumba | Kasai Central |
Congo, The Democratic Republic of the | Centre Evangélique de Coopération | Kimpese | Kongo Central |
Congo, The Democratic Republic of the | Centre de Santé de Référence Rutshuru | Rutshuru | Nord-Kivu |
Lead Sponsor | Collaborator |
---|---|
Ministry of Public Health, Democratic Republic of the Congo |
Congo, The Democratic Republic of the,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PCR-adjusted efficacy | the proportion of children with PCR adequate clinical and parasitological response | day 42 | |
Secondary | PCR-unadjusted efficacy | the proportion of children with treatment failure: all treatment failures detected during the follow-up, regardless of genotyping | day 42 | |
Secondary | K-13 propeller polymorphisms | the proportion of mutations in portions of P. falciparum gene encoding kelch(K-13)-propeller domains (confering resistance to artemisinin) | day 42 | |
Secondary | incidence of adverse events | monitoring of all adverse events experienced by participants | day 42 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Completed |
NCT02527005 -
A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients
|
Phase 1 |